People living with inflammatory and fibrotic diseases are at the center of Contineum’s mission.
Your contributions are important to our success and our goal of developing safe and effective treatments for serious diseases including idiopathic pulmonary fibrosis and chronic pain.
Patient Advocacy
We partner with advocacy and research groups to increase trial awareness in the patient communities we strive to serve.
You can potentially help change how serious neurological, inflammatory and fibrotic diseases are treated. An important part of developing new therapies is investigating them through clinical trials. Trials help us to better understand how treatments work, how effective they are, and if there are any risks or side effects. Your doctor will help you decide if taking part in a clinical trial is the right option for you.
Therapeutic Areas
in Focus
Idiopathic pulmonary fibrosis (IPF)
IPF is the most common type of idiopathic interstitial lung disease. More than 250,000 Americans are living with pulmonary fibrosis (PF), and IPF is one of the most common forms of PF. The prevalence of PF and interstitial lung disease is on the rise, with more than 50,000 new cases diagnosed annually.
Clinical Trials Now Enrolling
We have initiated patient dosing in PROPEL-IPF, a global Phase 2 clinical trial evaluating PIPE-791 for the treatment of patients with IPF. PROPEL-IPF is a 26-week, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy, safety, tolerability and pharmacokinetics of once-daily, oral PIPE-791 in approximately 324 IPF patients. The primary efficacy endpoint is the change from baseline through week 26 in absolute forced vital capacity (FVC mL). More information on this trial can be found at:
Contineum Clinical Trials
View more information on our trials
Additional resources, patient advocacy groups, community partners
